Abstract:Synthesis of new bioactive heterocyclic compounds bearing phosphorus and silicon moieties. The reaction of phosphacumulene and phosphallene ylides with iso(thio)cyanates resulted in the formation of different four‐, and six‐membered heterocyclic compounds containing one phosphorus or two phosphorus atoms. Molecular docking studies are carried out for the most active compounds 11 and 15 which are considered as potential MMP‐2 inhibitors. Matrix metalloproteinases (MMPs) attracted medicinal chemists as they are biological targets that are involved in various pathophysiological processes such as extracellular matrix protein degradation, cell‐surface receptor release and cleavage, tumor growth, homeostatic control, and innate immunity. New heterocycles, bearing both silicon and phosphorus in their molecular structures, were successfully produced via reacting silylated isocyanates and/or isothiocyanates with appropriate phosphorus ylides. Reacting nucleophilic phosphacumulenes (2,6) with isocyanate 1 and isothiocyanate 9 yielded four‐membered ring heterocycles containing phosphorus and silicon (4 and 11) and six‐membered rings heterocycles (5, 8 and 12). Moreover, novel heterocycles containing two phosphorus atoms and one silicon atom were produced by the reaction of diphosphorane 13 with 1 or 9. On the other side, four‐membered (23, 26 and 29a) and six‐membered heterocyclic derivatives (20b and 29b) containing two phosphorus atoms in their structures were also obtained from the reaction of phosphallene ylide 13 and substrates (18, 21, 24 and 27). All the final compounds were tested for their MMP‐2 inhibitor activity showing IC50 values in the range of 0.0408–0.4985 μM. The thiolactam derivative 11 and the azaphosphetidin‐4‐one derivative 15, both bearing silicon and phosphorous, showed the highest activity with IC50 values of 0.0408 and 0.0693 μM, respectively, both are significantly higher than that of quercetin (IC50 = 0.1631 μM). Docking simulations were carried out for the most two active compounds 11 and 15 in the vicinity of the active site of MMP‐2 enzyme and both formed coordinate bonds with the zinc cation key interaction for MMP‐2 enzyme. In conclusion, compounds 11 and 15 can be considered as potential MMP‐2 inhibitors and can be subjected to further studies as antimetastatic agents.

Phosphorus based inhibitors of matrix metalloproteinases

Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics

Matrix Metalloproteinases: New Targets in Cancer Therapy

Matrix metalloproteases: variations on a theme

Ligand and structure-based discovery of phosphorus-containing compounds as potential metalloproteinase inhibitors

Matrix metalloproteinases involvement in pathologic conditions

Design, synthesis, and biological evaluation of new heterocycles bearing both silicon and phosphorus as potent MMP‐2 inhibitors

Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Metabolism: Insights into Health and Disease

Recent developments in the synthesis and applications of phosphinic peptide analogs

The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases

Engineering metalloproteinase inhibitors: tissue inhibitors of metalloproteinases or antibodies, that is the question

Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization

Matrix metalloproteinases in dentin: Assessing their presence, activity, and inhibitors - a review of current trends

An in vitro tissue model for screening sustained release of phosphate-based therapeutic attenuation of pathogen-induced proteolytic matrix degradation

Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs

Matrix metalloproteinases at a glance

The role of matrix metalloproteinases in the oral environment

Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal

Matrix Metalloproteinases in Bone Resorption, Remodeling, and Repair

Biochemical insights into the role of matrix metalloproteinases in regeneration: challenges and recent developments

Modulation of Matrix Metalloproteinases by Plant-derived Products